{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:32:44Z","timestamp":1789860764512,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jaci.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T19:40:51Z","timestamp":1476128451000},"page":"1167-1175.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma"],"prefix":"10.1016","volume":"139","author":[{"given":"Steven W.","family":"Yancey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector G.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver N.","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabita","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necdet B.","family":"Gunsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene R.","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranabashis","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.08.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2049-6958-10-1","article-title":"Tailored therapy for severe asthma","volume":"10","author":"Menzella","year":"2015","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.08.008_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2016.08.008_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.008_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/all.12275","article-title":"EAACI position statement on asthma exacerbations and severe asthma","volume":"68","author":"Custovic","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.08.008_bib8","unstructured":"Global strategy for asthma management and prevention. 2016. Available at: http:\/\/ginasthma.org\/2016-gina-report-global-strategy-for-asthma-management-and-prevention\/. Accessed May 31, 2016."},{"key":"10.1016\/j.jaci.2016.08.008_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1081-1206(10)62832-3","article-title":"Risk factors for death from asthma. Prairie Provinces Asthma Study Group","volume":"83","author":"Hessel","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.08.008_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/thx.41.11.833","article-title":"A case-control study of deaths from asthma","volume":"41","author":"Rea","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2016.08.008_bib11","first-page":"265","article-title":"A systematic review of risk\u00a0factors associated with near-fatal and fatal asthma","volume":"12","author":"Alvarez","year":"2005","journal-title":"Can Respir J"},{"key":"10.1016\/j.jaci.2016.08.008_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.008_bib14","doi-asserted-by":"crossref","first-page":"e59872","DOI":"10.1371\/journal.pone.0059872","article-title":"Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2016.08.008_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib20","unstructured":"GSK. Meta-Analysis in sponsored studies MEA112997, MEA115588, and MEA115575 and a proof of concept investigator sponsored study CRT110184 of mepolizumab in severe asthma. 2015. Available at: http:\/\/www.gsk-clinicalstudyregister.com\/study\/204664?study_ids=204664#ps. Accessed May 31, 2016."},{"key":"10.1016\/j.jaci.2016.08.008_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/sim.2310","article-title":"The importance of varying the event generation process in simulation studies of statistical methods for recurrent events","volume":"25","author":"Metcalfe","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pst.397","article-title":"Reporting cumulative proportion of subjects\u00a0with\u00a0an adverse event based on data from multiple studies","volume":"10","author":"Chuang-Stein","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jaci.2016.08.008_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib25","unstructured":"GSK. A\u00a0multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels. 2014. Available at: http:\/\/www.gsk-clinicalstudyregister.com\/study\/114092?study_ids=114092#ps. Accessed May 31, 2016."},{"key":"10.1016\/j.jaci.2016.08.008_bib26","unstructured":"GSK. MEA115661: a multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials. 2016. Available at: http:\/\/www.gsk-clinicalstudyregister.com\/study\/115661?study_ids=115661#ps. Accessed May 30, 2016."},{"key":"10.1016\/j.jaci.2016.08.008_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/thoraxjnl-2014-205581","article-title":"Characterisation of an OCS-dependent severe asthma population treated with mepolizumab","volume":"69","author":"Prazma","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2016.08.008_bib28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.008_bib29","unstructured":"GSK. PGx7530: genetics of mepolizumab (SB240563) treatment response in severe asthmatics in MEA115588. 2015. Available at: http:\/\/www.gsk-clinicalstudyregister.com\/study\/201318?study_ids=201318#ps. Accessed May 31, 2016."},{"key":"10.1016\/j.jaci.2016.08.008_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/13543780902922678","article-title":"Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia","volume":"18","author":"Antoniu","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaci.2016.08.008_bib31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaip.2015.08.003","article-title":"Utilization and costs of severe uncontrolled asthma in a managed-care setting","volume":"4","author":"Zeiger","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2016.08.008_bib33","first-page":"CD010834","article-title":"Mepolizumab versus placebo for asthma","volume":"7","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2016.08.008_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200807-1126OC","article-title":"Severe exacerbations and decline in lung function in asthma","volume":"179","author":"O'Byrne","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2016.08.008_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2016.08.008_bib37","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway\u00a0hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.08.008_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2016.08.008_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.08.008_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916308910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916308910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:03:19Z","timestamp":1758790999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674916308910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0091674916308910"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.08.008","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 GlaxoSmithKline. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}